Kissei Pharmaceutical

4547.TPhase 3

Matsumoto, JapanFounded 1946kissei.co.jp

Kissei Pharmaceutical is a mid-sized, research-driven Japanese pharmaceutical company with a history spanning over 70 years. Its strategic focus lies in developing and marketing novel drugs for urological, nephrological, and metabolic disorders, while also engaging in licensing and collaborative partnerships to expand its portfolio. The company leverages its expertise in drug discovery and development to address unmet medical needs, with a commercial presence in Japan and through international partnerships. Its financial stability is supported by marketed products and a pipeline of clinical-stage candidates.

Market Cap

$1.2B

Founded

1946

Employees

1000-1500

Focus

Biotech

4547.T · Stock Price

USD 4535.00+2059.00 (+83.16%)

Historical price data

AI Company Overview

Technology Platform

Core expertise in medicinal chemistry and clinical development of small molecule therapeutics, with a specialized focus on urological, nephrological, and metabolic disorders.

Pipeline Snapshot

63 drugs in pipeline, 28 in Phase 3

Drug	Indication	Stage
Avacopan, prednisolone and rituximab + Prednisolone and rituximab	ANCA Associated Vasculitis (AAV)	Approved
KAD-1229 + Placebo + Insulin	Type 2 Diabetes Mellitus	Approved
KPS-0373, High dose + KPS-0373, Low dose	Spinocerebellar Degeneration	Phase 3
KCT-0809 ophthalmic solution + Placebo	Dry Eye With Sjögren's Syndrome	Phase 3
KCT-0809 ophthalmic solution	Dry Eye With Sjögren's Syndrome	Phase 3

Funding History

IPOUndisclosedUndisclosedMar 15, 2002

Opportunities

Growth opportunities include the successful market penetration of Uprifosbuvir in Japan, the potential approval and launch of mirogabalin for neuropathic pain, and the advancement of its Phase II pipeline in IBS-C and renal anemia.

Further out-licensing of assets for global development could provide non-dilutive funding and future royalties.

Risk Factors

Key risks include clinical trial failures in its late-stage pipeline, intense competition in all core therapeutic areas, dependence on the Japanese market and its pricing environment, and reliance on partners for the development of key assets.

Competitive Landscape

Kissei faces competition from large global pharma and generic companies in urology (PDE5 inhibitors), pain (Lyrica, generics), and nephrology (ESAs, HIF-PH inhibitors). Its differentiation lies in its specialized R&D focus, targeted product profiles, and strategic partnerships with larger Japanese pharmaceutical firms for development and commercialization.

Publications

Patents

Pipeline